Moderna and Revolution Medicines Announce Promising Cancer Therapy Results at AACR

The 2026 AACR Annual Meeting showcased significant advancements in biotechnology, with Moderna reporting positive Phase 1/2 data for its mRNA-4359 melanoma therapy, which achieved an 83% overall response rate when combined with pembrolizumab. Simultaneously, Revolution Medicines (RVMD) announced updated Phase 1 clinical data for zoldonrasib in patients with KRAS G12D non-small cell lung cancer (NSCLC). Zoldonrasib is an oral RAS(ON) G12D-selective inhibitor targeting RAS-addicted cancers, and its results were featured in the official AACR press program. These developments underscore the growing potential of both mRNA technology and targeted RAS inhibitors in oncology. Following these clinical milestones, the FDA's Fast Track designation for Moderna's therapy further bolsters investor sentiment across the biotech sector.